Pomerantz investigates Dr. Reddy’s after shares fall 9.4%

2026年9月1日21:41 (21d ago)

正在验证中

Pomerantz LLP is investigating Dr. Reddy’s over alleged securities fraud and unlawful business practices.
₹2.4 billion provision for rejected semaglutide batches contributed to $0.06 quarterly earnings per share.
Dr. Reddy’s shares fell 9.4% to $11.38 on July 22, 2026.

本网站上的信息是使用AI生成的，我们无法保证其准确性。请仅作为参考信息使用。